|
Thursday, October 18, 2018 |
|
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference |
Eisai Co., Ltd. announced today that five oral presentations including a symposium, and two poster presentations. more info >> |
|
Wednesday, October 17, 2018 |
|
エーザイとPurdue Pharma、「レンボレキサント」の不眠障害を対象とした2つめのピボタル臨床第III相試験(SUNRISE 2試験)において良好なトップライン結果を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とPurdue Pharma L.P.(本社:米国コネチカット州、President and CEO:Craig Landau、以下 Purdue Pharma)は、このたび、睡眠と覚醒を調整する薬剤として開発中のレンボレキサントに関して、長期の有効性および安全性評価を目的とする臨床第III相試験(SUNRISE 2試験/303試験)のプラセボを対照とした6カ月時点の解析において、良好なトップライン結果を得たことをお知らせします。 more info >> |
|
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant |
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders. more info >> |
|
Tuesday, October 16, 2018 |
|
エーザイ、肥満症治療剤lorcaserin Eurofarmaとラテンアメリカにおける提携契約を締結 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、肥満症治療剤lorcaserin hydrochloride(一般名、米国製品名:「BELVIQ(R)」、1日1回製剤米国製品名「BELVIQ XR(R)」、以下 lorcaserin)に関して、ブラジルを除くラテンアメリカおよびカリブ海域の17カ国*における独占的な開発および販売権を、ラテンアメリカに事業基盤を有するEurofarma Laboratórios S.A. (本社:ブラジル サンパウロ、President:Maurizio Billi、以下 Eurofarma)に付与する契約を締結しましたのでお知らせします。 more info >> |
|
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma |
Under this agreement, Eisai will supply Eurofarma with lorcaserin. Eisai will receive a one-time contractual payment and is eligible for milestone payments for development and sales in each country. more info >> |
|
Friday, October 12, 2018 |
|
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China |
This application for perampanel in partial onset seizures in China was based on the results of three Phase III clinical studies conducted mainly in Europe and the United States, as well as the results of a Phase III clinical study (Study 335) conducted mainly in Asia including China and Japan. more info >> |
|
Friday, February 16, 2018 |
|
Eisai: U.K. NICE Recommends Anticancer Agent Lenvima as Treatment for Thyroid Cancer |
Eisai Co., Ltd. announced today that its in-house developed anticancer agent Lenvima has been recommended by the U.K. NICE as a treatment for progressive, locally advanced or metastatic differentiated thyroid cancer in adults whose disease does not respond to radioactive iodine, in NICE's FAD. more info >> |
|
Tuesday, February 13, 2018 |
|
エーザイ、抗がん剤レンバチニブ 肝細胞がんにおける臨床第III相試験結果がThe Lancetに掲載 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩(一般名、製品名:「レンビマ(R)」「Kisplyx(R)」、以下 レンバチニブ)に関する肝細胞がんを対象とした臨床第III相試験(REFLECT/304試験)の結果が、世界的に最も権威のある医学雑誌の一つであり、最新の文献引用影響率が世界第二位のThe Lancet電子版に掲載されたことをお知らせします。 more info >> |
|
Monday, February 12, 2018 |
|
Eisai's Phase III Trial Results of Anticancer Agent Lenvatinib in Hepatocellular Carcinoma Published in The Lancet |
Eisai Co., Ltd. announced that the results of a Phase III study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylatein patients with hepatocellular carcinoma (HCC) have been published in the online version of The Lancet. more info >> |
|
Thursday, February 1, 2018 |
|
Eisai: Primary Endpoint Met in Phase II / III Clinical Study of Investigational Parkinson's Disease Treatment Safinamide in Japan |
Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that the primary endpoint was met in a Phase II/III clinical study on the investigational Parkinson's disease treatment ME2125 in patients with Parkinson's disease. more info >> |
|
|
|